Data Science Funding Announcements & Notices
Data science and informatics funding announcements and notices are available from NCI and NIH programs. Browse below for opportunities, requests for information, notices, and initiatives.
| Title | FOA | Organization | Release Date | Expire Date | Purpose |
|---|---|---|---|---|---|
| The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 Clinical Trial Not Allowed) | RFA-CA-23-042 | NCI | The purpose of the NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to encourage and retain outstanding graduate students recognized by their institutions for their high potential… More | ||
| Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 Clinical Trial Optional) | PAR-21-138 | NCI | The National Cancer Institute (NCI) Method to Extend Research in Time (MERIT) (R37) Award provides extended grant support to Early Stage Investigators (ESIs). By providing such an opportunity for… More | ||
| Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine (U01 Clinical Trial Optional) | RFA-CA-24-006 | NCI | Through this Notice of Funding Opportunity Announcement (NOFO), the National Cancer Institute (NCI) intends to expand the research scope and leverage the gains made through the NOFO entitled… More | ||
| Notice of Special Interest (NOSI): Technologies and Informatics Tools for Cancer Metabolomics | NOT-CA-22-083 | NCI | This Notice of Special Interest (NOSI) is to alert the community that the National Cancer Institute (NCI) is seeking to support development of innovative technologies and informatics tools for… More | ||
| Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed) | PAR-21-294 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to invite research grant applications (R01) for the development and use of current and emerging molecular imaging methods to gain… More | ||
| Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed) | PAR-22-090 | NCI | The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to… More | ||
| Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed) | PAR-22-062 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory/development basic research projects that elucidate mechanisms by which the human microbiome inhibit or enhance… More | ||
| Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional) | PAR-22-091 | NCI | The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to… More | ||
| Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01 Clinical Trial Not Allowed) | PAR-22-061 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to support basic research that elucidates mechanisms by which the human microbiome inhibit or enhance anti-tumor immune responses, and to… More | ||
| Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional) | PAR-21-321 | NCI | This Funding Opportunity Announcement (FOA) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-designated Cancer Centers. CCSGs support three types of Cancer Centers: 1… More |